Market Closed -
Nasdaq Stockholm
11:29:55 2024-06-04 am EDT
|
5-day change
|
1st Jan Change
|
2.475
SEK
|
-1.20%
|
|
+22.52%
|
-38.28%
|
Fiscal Period: December |
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
730.2
|
552.1
|
191.2
|
257.1
|
275.3
|
-
|
Enterprise Value (EV)
1 |
691.4
|
552.1
|
191.2
|
257.1
|
271.1
|
275.3
|
P/E ratio
|
-
|
-1.34
x
|
-0.78
x
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
270
x
|
-
|
12.5
x
|
15.3
x
|
4.44
x
|
4.92
x
|
EV / Revenue
|
256
x
|
-
|
12.5
x
|
15.3
x
|
4.37
x
|
4.92
x
|
EV / EBITDA
|
-6.8
x
|
-
|
-0.88
x
|
-3.6
x
|
-10
x
|
-8.6
x
|
EV / FCF
|
-6.78
x
|
-
|
-0.68
x
|
-3
x
|
-7.75
x
|
-14.5
x
|
FCF Yield
|
-14.7%
|
-
|
-148%
|
-33.3%
|
-12.9%
|
-6.9%
|
Price to Book
|
12.2
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
28,413
|
62,386
|
62,386
|
64,127
|
111,238
|
-
|
Reference price
2 |
25.70
|
8.850
|
3.065
|
4.010
|
2.475
|
2.475
|
Announcement Date
|
2/7/20
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2.7
|
-
|
15.28
|
16.84
|
62
|
56
|
EBITDA
1 |
-101.7
|
-
|
-217.9
|
-71.41
|
-27
|
-32
|
EBIT
1 |
-103.9
|
-
|
-225.7
|
-81.06
|
-29
|
-38
|
Operating Margin
|
-3,848.15%
|
-
|
-1,476.93%
|
-481.38%
|
-46.77%
|
-67.86%
|
Earnings before Tax (EBT)
1 |
-83.5
|
-
|
-252
|
-104.3
|
-37
|
-43
|
Net income
1 |
-75.8
|
-410.9
|
-245.4
|
-95.81
|
-37
|
-43
|
Net margin
|
-2,807.41%
|
-
|
-1,605.42%
|
-568.94%
|
-59.68%
|
-76.79%
|
EPS
|
-
|
-6.590
|
-3.930
|
-
|
-
|
-
|
Free Cash Flow
1 |
-102
|
-
|
-282.5
|
-85.66
|
-35
|
-19
|
FCF margin
|
-3,776.19%
|
-
|
-1,848.6%
|
-508.67%
|
-56.45%
|
-33.93%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/7/20
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
38.8
|
-
|
-
|
-
|
4.2
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-102
|
-
|
-283
|
-85.7
|
-35
|
-19
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-84.6%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
89.55
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
2.100
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
3.49
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
129.19%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/7/20
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -38.28% | 26.75M | | +16.73% | 121B | | +13.04% | 107B | | -5.80% | 24.82B | | +1.69% | 22.48B | | -10.09% | 18.32B | | -40.52% | 16.33B | | -14.00% | 15.31B | | +1.18% | 14.08B | | +24.18% | 11.74B |
Bio Therapeutic Drugs
|